Lumosa Therapeutics Co., Ltd.

Taipei Exchange 6535.TWO

Lumosa Therapeutics Co., Ltd. Free Cash Flow Yield on January 14, 2025: -0.83%

Lumosa Therapeutics Co., Ltd. Free Cash Flow Yield is -0.83% on January 14, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Lumosa Therapeutics Co., Ltd. 52-week high Free Cash Flow Yield is -0.56% on October 28, 2024, which is 31.76% above the current Free Cash Flow Yield.
  • Lumosa Therapeutics Co., Ltd. 52-week low Free Cash Flow Yield is -1.26% on December 16, 2024, which is -52.73% below the current Free Cash Flow Yield.
  • Lumosa Therapeutics Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is -0.83%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
Taipei Exchange: 6535.TWO

Lumosa Therapeutics Co., Ltd.

CEO Li Fang Pan
IPO Date July 16, 2015
Location
Headquarters No. 3-2, Park Street
Employees 47
Sector Health Care
Industries
Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email